Secreted proteins in treating metabolic dysfunction-associated steatotic liver disease: from bench towards bedside

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a global epidemic, yet effective pharmacological treatments remain limited. Secreted proteins play diverse roles in regulating glucose and lipid metabolism, and their dysregulation is implicated in the development of various metabolic diseases, including MASLD. Therefore, targeting secreted proteins and modulating associated signaling pathways represents a promising therapeutic strategy for MASLD. In this review, we summarize recent findings on the roles of emerging families of secreted proteins in MASLD and related metabolic disorders. These include the orosomucoid (ORM) family, secreted acidic cysteine rich glycoprotein (SPARC) family, neuregulin (Nrg) family, growth differentiation factor (GDF) family, interleukin (IL) family, fibroblast growth factor (FGF) family, bone morphogenic protein (BMP) family, as well as isthmin-1 (Ism1) and mesencephalic astrocyte-derived neurotrophic factor (MANF). The review highlights their impact on glucose and lipid metabolism and discusses the clinical potential of targeting these secreted proteins as a therapeutic approach for MASLD.

Keywords

secreted proteins / metabolic dysfunction-associated steatotic liver disease / metabolic dysfunction-associated steatohepatitis / hepatic lipid metabolism / clinical application

References

[1] Abdelmalek MF, Sanyal AJ, Nakajima A et al. Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized phase 2b study. Clin Gastroenterol Hepatol 2024;22:113–123.e9.

[2] Abdelnabi MN, Flores Molina M, Soucy G et al. Sex-dependent hepatoprotective role of IL-22 receptor signaling in non-alcoholic fatty liver disease-related fibrosis. Cell Mol Gastroenterol Hepatol 2022;14:1269–1294.

[3] Adams AC, Halstead CA, Hansen BC et al. LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys. PLoS One 2013;8:e65763.

[4] Ahuja P, Bi X, Ng CF et al. Src homology 3 domain binding kinase 1 protects against hepatic steatosis and insulin resistance through the Nur77-FGF21 pathway. Hepatology 2023;77:213–229.

[5] Alfadda AA, Fatma S, Chishti MA et al. Orosomucoid serum concentrations and fat depot-specific mRNA and protein expression in humans. Mol Cells 2012;33:35–41.

[6] Alisi A, Ceccarelli S, Panera N et al. Association between serum atypical fibroblast growth factors 21 and 19 and pediatric nonalcoholic fatty liver disease. PLoS One 2013;8:e67160.

[7] Alvarez-Sola G, Uriarte I, Latasa MU et al. Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration. Gut 2017;66:1818–1828.

[8] Al-Zuhairi WS, Sadeghi L, Hassan EA. The link between serum neuregulin-1 and atherogenic index in type 2 diabetes mellitus. Ir J Med Sci 2024;193:2209–2216.

[9] Ameka M, Markan KR, Morgan DA et al. Liver derived FGF21 maintains core body temperature during acute cold exposure. Sci Rep 2019;9:630.

[10] Arab JP, Sehrawat TS, Simonetto DA et al. An open-label, dose-escalation study to assess the safety and efficacy of IL-22 agonist F-652 in patients with alcohol-associated hepatitis. Hepatology 2020;72:441–453.

[11] Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 2008;223:20–38.

[12] Arndt S, Wacker E, Dorn C et al. Enhanced expression of BMP6 inhibits hepatic fibrosis in non-alcoholic fatty liver disease. Gut 2015;64:973–981.

[13] Arshad T, Mansur F, Palek R et al. A double edged sword role of interleukin-22 in wound healing and tissue regeneration. Front Immunol 2020;11:2148.

[14] Asadikaram G, Akbari H, Safi Z et al. Downregulation of IL-22 can be considered as a risk factor for onset of type 2 diabetes. J Cell Biochem 2018;119:9254–9260.

[15] Atorrasagasti C, Aquino JB, Hofman L et al. SPARC downregulation attenuates the profibrogenic response of hepatic stellate cells induced by TGF-beta1 and PDGF. Am J Physiol Gastrointest Liver Physiol 2011;300:G739–G748.

[16] Atorrasagasti C, Onorato A, Gimeno ML et al. SPARC is required for the maintenance of glucose homeostasis and insulin secretion in mice. Clin Sci 2019;133:351–365.

[17] Atorrasagasti C, Peixoto E, Aquino JB et al. Lack of the matricellular protein SPARC (secreted protein, acidic and rich in cysteine) attenuates liver fibrogenesis in mice. PLoS One 2013;8:e54962.

[18] Baboota RK, Rawshani A, Bonnet L et al. BMP4 and Gremlin 1 regulate hepatic cell senescence during clinical progression of NAFLD/NASH. Nat Metab 2022;4:1007–1021.

[19] Badman MK, Pissios P, Kennedy AR et al. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007;5:426–437.

[20] Bai J, Xia M, Xue Y et al. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans. EBioMedicine 2020;57:102849.

[21] Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8:235–253.

[22] Belkaya S, Michailidis E, Korol CB et al. Inherited IL-18BP deficiency in human fulminant viral hepatitis. J Exp Med 2019;216:1777–1790.

[23] Bell LN, Lee L, Saxena R et al. Serum proteomic analysis of diet-induced steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Am J Physiol Gastrointest Liver Physiol 2010;298:G746–G754.

[24] Benichou O, Coskun T, Gonciarz MD et al. Discovery, development, and clinical proof of mechanism of LY3463251, a long-actin. GDF15 receptor agonist. Cell Metab 2023;35:274–286.e10.

[25] Berglund ED, Li CY, Bina HA et al. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 2009;150:4084–4093.

[26] Bhatnagar S, Damron HA, Hillgartner FB. Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J Biol Chem 2009;284:10023–10033.

[27] Bhatt DL, Bays HE, Miller M et al; ENTRIGUE Principal Investigators. The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial. Nat Med 2023;29:1782–1792.

[28] Blanc V, Riordan JD, Soleymanjahi S et al. Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis, and hepatocellular cancer. J Clin Invest 2021;131:e138699.

[29] Blazejewski S, Le Bail B, Boussarie L et al. Osteonectin (SPARC) expression in human liver and in cultured human liver myofibroblasts. Am J Pathol 1997;151:651–657.

[30] Boger CA, Sedor JR. GWAS of diabetic nephropathy: is the GENIE out of the bottle? PLoS Genet 2012;8:e1002989.

[31] Bograya M, Vulf M, Minchenko A et al. The putative antilipogenic role of NRG4 and ERBB4: first expression study on human liver samples. Front Biosci 2024;29:414.

[32] BonDurant LD, Ameka M, Naber MC et al. FGF21 regulates metabolism through adipose-dependent and -independent mechanisms. Cell Metab 2017;25:935–944.e4.

[33] BonDurant LD, Potthoff MJ. Fibroblast growth factor 21: a versatile regulator of metabolic homeostasis. Annu Rev Nutr 2018;38:173–196.

[34] Bookout AL, de Groot MH, Owen BM et al. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat Med 2013;19:1147–1152.

[35] Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 2001;107:1049–1054.

[36] Breit SN, Brown DA, Tsai VW. The GDF15-GFRAL pathway in health and metabolic disease: friend or foe? Annu Rev Physiol 2021;83:127–151.

[37] Breit SN, Manandhar R, Zhang HP et al. GDF15 enhances body weight and adiposity reduction in obese mice by leveraging the leptin pathway. Cell Metab 2023;35:1341–1355.e3.

[38] Breitkopf-Heinlein K, Meyer C, Konig C et al. BMP-9 interferes with liver regeneration and promotes liver fibrosis. Gut 2017;66:939–954.

[39] Bu Y, Okunishi K, Yogosawa S et al. Insulin regulates lipolysis and fat mass by upregulating growth/differentiation factor 3 in adipose tissue macrophages. Diabetes 2018;67:1761–1772.

[40] Burden S, Yarden Y. Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis. Neuron 1997;18:847–855.

[41] Byun S, Seok S, Kim YC et al. Fasting-induced FGF21 signaling activates hepatic autophagy and lipid degradation via JMJD3 histone demethylase. Nat Commun 2020;11:807.

[42] Cai C, Lin M, Xu Y et al. Association of circulating neuregulin 4 with metabolic syndrome in obese adults: a crosssectional study. BMC Med 2016;14:165.

[43] Caillaud K, Boisseau N, Ennequin G et al. Neuregulin 1 improves glucose tolerance in adult and old rats. Diabetes Metab 2016;42:96–104.

[44] Camino AM, Atorrasagasti C, Maccio D et al. Adenovirusmediated inhibition of SPARC attenuates liver fibrosis in rats. J Gene Med 2008;10:993–1004.

[45] Canto C, Pich S, Paz JC et al. Neuregulins increase mitochondrial oxidative capacity and insulin sensitivity in skeletal muscle cells. Diabetes 2007;56:2185–2193.

[46] Casana E, Jimenez V, Jambrina C et al. AAV-mediated BMP7 gene therapy counteracts insulin resistance and obesity. Mol Ther Methods Clin Dev 2022;25:190–204.

[47] Cespedes JC, Liu M, Harbuzariu A et al. Neuregulin in health and disease. Int J Brain Disord Treat 2018;4:024.

[48] Chen MZ, Chang JC, Zavala-Solorio J et al. FGF21 mimetic antibody stimulates UCP1-independent brown fat thermogenesis via FGFR1/βKlotho complex in nonadipocytes. Mol Metab 2017a;6:1454–1467.

[49] Chen Z, Wang GX, Ma SL et al. Nrg4 promotes fuel oxidation and a healthy adipokine profile to ameliorate dietinduced metabolic disorders. Mol Metab 2017b;6:863–872.

[50] Chen L, Xuan Y, Zhu Y et al. Adipocyte secreted NRG4 ameliorates age-associated metabolic dysfunction. Biochem Pharmacol 2024a;225:116327.

[51] Chen Z, Zhang P, Liu T et al. Neuregulin 4 mediates the metabolic benefits of mild cold exposure by promoting beige fat thermogenesis. JCI Insight 2024b;9:e172957.

[52] Chen ZT, Weng ZX, Lin JD et al. Myokines: metabolic regulation in obesity and type 2 diabetes. Life Metab. 2024c;3:loae006.

[53] Chen M, Li Y, Zhu JY et al. Exercise-induced adipokine Nrg4 alleviates MASLD by disrupting hepatic cGAS-STING signaling. Cell Rep 2025;44:115251.

[54] Chrysovergis K, Wang X, Kosak J et al. NAG-1/GDF-15 prevents obesity by increasing thermogenesis, lipolysis and oxidative metabolism. Int J Obes 2014;38:1555–1564.

[55] Chui ZSW, Shen Q, Xu A. Current status and future perspectives of FGF21 analogues in clinical trials. Trends Endocrinol Metab 2024;35:371–384.

[56] Chung HK, Ryu D, Kim KS et al. Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis. J Cell Biol 2017;216:149–165.

[57] Coskun T, Bina HA, Schneider MA et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008;149:6018–6027.

[58] Dai YN, Zhu JZ, Fang ZY et al. A case-control study: association between serum neuregulin 4 level and non-alcoholic fatty liver disease. Metabolism 2015;64:1667–1673.

[59] Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998;114:842–845.

[60] Degirolamo C, Sabba C, Moschetta A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov 2016;15:51–69.

[61] DePaoli AM, Zhou M, Kaplan DD et al. FGF19 analog as a surgical factor mimetic that contributes to metabolic effects beyond glucose homeostasis. Diabetes 2019;68:1315–1328.

[62] Dudakov JA, Hanash AM, van den Brink MR. Interleukin-22: immunobiology and pathology. Annu Rev Immunol 2015;33:747–785.

[63] Eldin AS, Fawzy O, Mahmoud E et al. Serum neuregulin 1 in relation to ventricular function and subclinical atherosclerosis in type 2 diabetes patients. Endocrinol Diabetes Nutr (Engl Ed) 2023;70:619–627.

[64] Emmerson PJ, Wang F, Du Y et al. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. Nat Med 2017;23:1215–1219.

[65] Ennequin G, Boisseau N, Caillaud K et al. Neuregulin 1 improves glucose tolerance in db/db mice. PLoS One 2015;10:e0130568.

[66] Ennequin G, Capel F, Caillaud K et al. Neuregulin 1 improves complex 2-mediated mitochondrial respiration in skeletal muscle of healthy and diabetic mice. Sci Rep 2017;7:1742.

[67] Eren F, Kurt R, Ermis F et al. Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. Clin Biochem 2012;45:655–658.

[68] Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010;51:679–689.

[69] Feingold KR, Grunfeld C, Heuer JG et al. FGF21 is increased by inflammatory stimuli and protects leptin-deficient ob/ob mice from the toxicity of sepsis. Endocrinology 2012;153:2689–2700.

[70] Feng G, Valenti L, Wong VW et al. Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2024;21:46–56.

[71] Fischer CP, Perstrup LB, Berntsen A et al. Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans. Clin Immunol 2005;117:152–160.

[72] Fisher FM, Chui PC, Nasser IA et al. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology 2014;147:1073–83.e6.

[73] Fisher FM, Maratos-Flier E. Understanding the physiology of FGF21. Annu Rev Physiol 2016;78:223–241.

[74] Flippo KH, Jensen-Cody SO, Claflin KE et al. FGF21 signaling in glutamatergic neurons is required for weight loss associated with dietary protein dilution. Sci Rep 2020;10:19521.

[75] Flippo KH, Potthoff MJ. Metabolic messengers: FGF21. Nat Metab 2021;3:309–317.

[76] Friedman SL, Neuschwander-Tetri BA, Rinella M et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018;24:908–922.

[77] Frizell E, Liu SL, Abraham A et al. Expression of SPARC in normal and fibrotic livers. Hepatology 1995;21:847–854.

[78] Fu L, John LM, Adams SH et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptindeficient diabetes. Endocrinology 2004;145:2594–2603.

[79] Gagliardi F, Narayanan A, Mortini P. SPARCL1 a novel player in cancer biology. Crit Rev Oncol Hematol 2017;109:63–68.

[80] Gaich G, Chien JY, Fu H et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 2013;18:333–340.

[81] Gateva A, Kamenov Z, Karamfilova V et al. Higher levels of IL-18 in patients with prediabetes compared to obese normoglycaemic controls. Arch Physiol Biochem 2020;126:449–452.

[82] Gaudino SJ, Singh A, Huang H et al. Intestinal IL-22RA1 signaling regulates intrinsic and systemic lipid and glucose metabolism to alleviate obesity-associated disorders. Nat Commun 2024;15:1597.

[83] Gavalda-Navarro A, Villarroya J, Cereijo R et al. The endocrine role of brown adipose tissue: an update on actors and actions. Rev Endocr Metab Disord 2022;23:31–41.

[84] Geissler A, Ryzhov S, Sawyer DB. Neuregulins: protective and reparative growth factors in multiple forms of cardiovascular disease. Clin Sci 2020;134:2623–2643.

[85] Geng L, Lam KSL, Xu A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol 2020;16:654–667.

[86] Gomes MB, Piccirillo LJ, Nogueira VG et al. Acute-phase proteins among patients with type 1 diabetes. Diabetes Metab 2003;29:405–411.

[87] Gong F, Wu J, Zhou P et al. Interleukin-22 might act as a double-edged sword in type 2 diabetes and coronary artery disease. Mediators Inflamm 2016;2016:8254797.

[88] Gu J, Zhou P, Liu Y et al. Down-regulating Interleukin-22/Interleukin-22 binding protein axis promotes inflammation and aggravates diet-induced metabolic disorders. Mol Cell Endocrinol 2022;557:111776.

[89] Guma A, Diaz-Saez F, Camps M et al. Neuregulin, an effector on mitochondria metabolism that preserves insulin sensitivity. Front Physiol 2020;11:696.

[90] Guo D, Liu J, Zhang P et al. Adiposity measurements and metabolic syndrome are linked through circulating neuregulin 4 and adipsin levels in obese adults. Front Physiol 2021;12:667330.

[91] Guo L, Zhang P, Chen Z et al. Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-to-NASH progression. J Clin Invest 2017;127:4449–4461.

[92] Hall JA, Ramachandran D, Roh HC et al. Obesity-linked PPARgamma S273 phosphorylation promotes insulin resistance through growth differentiation factor 3. Cell Metab 2020;32:665–675.e6.

[93] Han S, Lone MA, Schneiter R et al. Orm1 and Orm2 are conserved endoplasmic reticulum membrane proteins regulating lipid homeostasis and protein quality control. Proc Natl Acad Sci U S A 2010;107:5851–5856.

[94] Hansen JS, Clemmesen JO, Secher NH et al. Glucagon-toinsulin ratio is pivotal for splanchnic regulation of FGF-21 in humans. Mol Metab 2015;4:551–560.

[95] Harari D, Tzahar E, Romano J et al. Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene 1999;18:2681–2689.

[96] Harries LW, McCulloch LJ, Holley JE et al. A role for SPARC in the moderation of human insulin secretion. PLoS One 2013;8:e68253.

[97] Harrison SA, Abdelmalek MF, Neff G et al. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol 2022;7:603–616.

[98] Harrison SA, Bedossa P, Guy CD et al; MAESTRO-NASH Investigators. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med 2024a;390:497–509.

[99] Harrison SA, Frias JP, Lucas KJ et al. Safety and efficacy of efruxifermin in combination with a GLP-1 receptor agonist in patients with NASH/MASH and Type 2 diabetes in a randomized phase 2 study. Clin Gastroenterol Hepatol 2025;23:103–113.

[100] Harrison SA, Frias JP, Neff G et al; HARMONY Study Group. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebocontrolled, phase 2b trial. Lancet Gastroenterol Hepatol 2023a;8:1080–1093.

[101] Harrison SA, Neff G, Guy CD et al. Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis. Gastroenterology 2021a;160:219–231.e1.

[102] Harrison SA, Rinella ME, Abdelmalek MF et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2018;391:1174–1185.

[103] Harrison SA, Rolph T, Knott M et al. FGF21 agonists: an emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond. J Hepatol 2024b;81:562–576.

[104] Harrison SA, Rossi SJ, Paredes AH et al. NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis. Hepatology 2020;71:1198–1212.

[105] Harrison SA, Ruane PJ, Freilich BL et al. Efruxifermin in non-alcoholic steatohepatitis: a randomized, doubleblind, placebo-controlled, phase 2a trial. Nat Med 2021b;27:1262–1271.

[106] Harrison SA, Ruane PJ, Freilich B et al. A randomized, doubleblind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. JHEP Rep 2023b;5:100563.

[107] Hasnain SZ, Borg DJ, Harcourt BE et al. Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress. Nat Med 2014;20:1417–1426.

[108] He M, Wang C, Long XH et al. Mesencephalic astrocytederived neurotrophic factor ameliorates steatosis in HepG2 cells by regulating hepatic lipid metabolism. World J Gastroenterol 2020;26:1029–1041.

[109] Henao-Mejia J, Elinav E, Jin C et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012;482:179–185.

[110] Heo MJ, Cheon I, Kim KH. More than carriers, orosomucoids are key metabolic modulators. Trends Endocrinol Metab 2024:S1043-2760(24)00322-9.

[111] Herpin A, Lelong C, Favrel P. Transforming growth factorbeta-related proteins: an ancestral and widespread superfamily of cytokines in metazoans. Dev Comp Immunol 2004;28:461–485.

[112] Hill CM, Laeger T, Dehner M et al. FGF21 signals protein status to the brain and adaptively regulates food choice and metabolism. Cell Rep 2019;27:2934–2947.e3.

[113] Hochepied T, Berger FG, Baumann H et al. α₁-Acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev 2003;14:25–34.

[114] Hohenester S, Kanitz V, Schiergens T et al. IL-18 but Not IL-1 signaling is pivotal for the initiation of liver injury in murine non-alcoholic fatty liver disease. Int J Mol Sci 2020;21:8602.

[115] Hou C, Wang D, Zhao M et al. MANF brakes TLR4 signaling by competitively binding S100A8 with S100A9 to regulate macrophage phenotypes in hepatic fibrosis. Acta Pharm Sin B 2023;13:4234–4252.

[116] Hsiao EC, Koniaris LG, Zimmers-Koniaris T et al. Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury. Mol Cell Biol 2000;20:3742–3751.

[117] Hsu JY, Crawley S, Chen M et al. Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. Nature 2017;550:255–259.

[118] Hu L, He F, Huang M et al. SPARC promotes insulin secretion through down-regulation of RGS4 protein in pancreatic β cells. Sci Rep 2020;10:17581.

[119] Huang Z, Ung T. Effect of alpha-1-acid glycoprotein binding on pharmacokinetics and pharmacodynamics. Curr Drug Metab 2013;14:226–238.

[120] Huang DQ, Singal AG, Kono Y et al. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab 2022;34:969–977.e2.

[121] Huang Y, Gao P, Young LH et al. Targeting white adipose tissue to combat insulin resistance. Trends Pharmacol Sci 2024;45:868–871.

[122] Huang Y, Yu F, Ding Y et al. Hepatic IL22RA1 deficiency promotes hepatic steatosis by modulating oxysterol in the liver. Hepatology 2025;81:1564–1582.

[123] Hwang S, He Y, Xiang X et al. Interleukin-22 ameliorates neutrophil-driven nonalcoholic steatohepatitis through multiple targets. Hepatology 2020;72:412–429.

[124] Icer MA, Gezmen-Karadag M. The multiple functions and mechanisms of osteopontin. Clin Biochem 2018;59:17–24.

[125] Imaeda AB, Watanabe A, Sohail MA et al. Acetaminopheninduced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest 2009;119:305–314.

[126] Irmak S, Oliveira-Ferrer L, Singer BB et al. Pro-angiogenic properties of orosomucoid (ORM). Exp Cell Res 2009;315:3201–3209.

[127] Izumi T. The GDF3-ALK7 signaling axis in adipose tissue: a possible therapeutic target for obesity and associated diabetes? Endocr J 2023;70:761–770.

[128] Jensen-Cody SO, Flippo KH, Claflin KE et al. FGF21 signals to glutamatergic neurons in the ventromedial hypothalamus to suppress carbohydrate intake. Cell Metab 2020;32:273–286.e6.

[129] Jensen-Cody SO, Potthoff MJ. Hepatokines and metabolism: deciphering communication from the liver. Mol Metab 2021;44:101138.

[130] Ji Y, Duan Y, Li Y et al. A long-acting FGF21 attenuates metabolic dysfunction-associated steatohepatitisrelated fibrosis by modulating NR4A1-mediated Ly6C phenotypic switch in macrophages. Br J Pharmacol 2024;181:2923–2946.

[131] Jiang Q, Li Q, Liu B et al. BMP9 promotes methionine-and choline-deficient diet-induced nonalcoholic steatohepatitis in non-obese mice by enhancing NF-κB dependent macrophage polarization. Int Immunopharmacol 2021a;96:107591.

[132] Jiang R, Tan Z, Deng L et al. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 2011;54:900–909.

[133] Jiang Z, Zhao M, Voilquin L et al. Isthmin-1 is an adipokine that promotes glucose uptake and improves glucose tolerance and hepatic steatosis. Cell Metab 2021b;33:1836–1852.e11.

[134] Jiao J, Zhao X, Liang Y et al. FGF1-FGFR1 axis promotes tongue squamous cell carcinoma (TSCC) metastasis through epithelial-mesenchymal transition (EMT). Biochem Biophys Res Commun 2015;466:327–332.

[135] Jing K, Gu R, Chen F et al. Orosomucoid 2 is an endogenous regulator of neuronal mitochondrial biogenesis and promotes functional recovery post-stroke. Pharmacol Res 2024;209:107422.

[136] Jonker JW, Suh JM, Atkins AR et al. A PPARgamma-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature 2012;485:391–394.

[137] Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci 2014;15:6184–6223.

[138] Kaplanski G. Interleukin-18: biological properties and role in disease pathogenesis. Immunol Rev 2018;281:138–153.

[139] Kharitonenkov A, Shiyanova TL, Koester A et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005;115:1627–1635.

[140] Kharitonenkov A, Wroblewski VJ, Koester A et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007;148:774–781.

[141] Kim S, Choe S, Lee DK. BMP-9 enhances fibroblast growth factor 21 expression and suppresses obesity. Biochim Biophys Acta 2016;1862:1237–1246.

[142] Kim HJ, Kang ES, Kim DJ et al. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clin Endocrinol 2007;66:282–289.

[143] Kim KH, Kim SH, Han DH et al. Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice. Sci Rep 2018;8:6789.

[144] Kim SH, Kim KH, Kim HK et al. Fibroblast growth factor 21 participates in adaptation to endoplasmic reticulum stress and attenuates obesity-induced hepatic metabolic stress. Diabetologia 2015;58:809–818.

[145] Kir S, Beddow SA, Samuel VT et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 2011;331:1621–1624.

[146] Klingler A, Regensburger D, Tenkerian C et al. Species-, organand cell-type-dependent expression of SPARCL1 in human and mouse tissues. PLoS One 2020;15:e0233422.

[147] Knorr J, Kaufmann B, Inzaugarat ME et al. Interleukin-18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis. Hepatology 2023;77:1968–1982.

[148] Kong X, Feng D, Wang H et al. Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology 2012;56:1150–1159.

[149] Koo BK, Um SH, Seo DS et al. Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven nonalcoholic fatty liver disease. Liver Int 2018;38:695–705.

[150] Kos K, Wilding JP. SPARC: a key player in the pathologies associated with obesity and diabetes. Nat Rev Endocrinol 2010;6:225–235.

[151] Kurosu H, Choi M, Ogawa Y et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007;282:26687–26695.

[152] Kwabi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 2004;11:709–724.

[153] Lan T, Morgan DA, Rahmouni K et al. FGF19, FGF21, and an FGFR1/beta-Klotho-activating antibody act on the nervous system to regulate body weight and glycemia. Cell Metab 2017;26:709–718.e3.

[154] Lana JP, Martins LB, Oliveira MC et al. TNF and IL-18 cytokines may regulate liver fat storage under homeostasis conditions. Appl Physiol Nutr Metab 2016;41:1295–1302.

[155] Lebel-Binay S, Berger A, Zinzindohoue F et al. Interleukin-18: biological properties and clinical implications. Eur Cytokine Netw 2000;11:15–26.

[156] Lee YS, Choi JW, Hwang I et al. Adipocytokine orosomucoid integrates inflammatory and metabolic signals to preserve energy homeostasis by resolving immoderate inflammation. J Biol Chem 2010;285:22174–22185.

[157] Lee SH, Choi JM, Jung SY et al. The bile acid induced hepatokine orosomucoid suppresses adipocyte differentiation. Biochem Biophys Res Commun 2021;534:864–870.

[158] Lee JH, Kang YE, Chang JY et al. An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function. Am J Transl Res 2016;8:4750–4763.

[159] Lee SH, Lee JA, Park HS et al. Associations among SPARC mRNA expression in adipose tissue, serum SPARC concentration and metabolic parameters in Korean women. Obesity 2013;21:2296–2302.

[160] Li L, Chen J, Sun H et al. Orm2 deficiency aggravates highfat diet-induced obesity through gut microbial dysbiosis and intestinal inflammation. Mol Nutr Food Res 2024;68:e2300236.

[161] Li Y, Jin L, Jiang F et al. Mutations of NRG4 contribute to the pathogenesis of nonalcoholic fatty liver disease and related metabolic disorders. Diabetes 2021;70:2213–2224.

[162] Li Y, Li-Li Z, Qin L et al. Plasma interleukin-18/interleukin-18 binding protein ratio in Chinese with NAFLD. Hepatogastroenterology 2010;57:103–106.

[163] Li L, Sun H, Chen J et al. Mitigation of non-alcoholic steatohepatitis via recombinant Orosomucoid 2, an acute phase protein modulating the Erk1/2-PPARgamma-Cd36 pathway. Cell Rep 2023;42:112697.

[164] Li Y, Wong K, Giles A et al. Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21. Gastroenterology 2014;146:539–549.

[165] Li D, Zhang H, Zhong Y. Hepatic GDF15 is regulated by CHOP of the unfolded protein response and alleviates NAFLD progression in obese mice. Biochem Biophys Res Commun 2018;498:388–394.

[166] Liang Q, Zhong L, Zhang J et al. FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting. Diabetes 2014;63:4064–4075.

[167] Lin Q, Huang Z, Cai G et al. Activating adenosine monophosphate-activated protein kinase mediates fibroblast growth factor 1 protection from nonalcoholic fatty liver disease in mice. Hepatology 2021;73:2206–2222.

[168] Lindemans CA, Calafiore M, Mertelsmann AM et al. Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration. Nature 2015;528:560–564.

[169] Liu X, Gu X, Li Z et al. Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol 2006;48:1438–1447.

[170] Liu W, Struik D, Nies VJ et al. Effective treatment of steatosis and steatohepatitis by fibroblast growth factor 1 in mouse models of nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A 2016;113:2288–2293.

[171] Liu J, Wu Z, Han D et al. Mesencephalic astrocyte-derived neurotrophic factor inhibits liver cancer through small ubiquitin-related modifier (SUMO)ylation-related suppression of NF-κB/Snail signaling pathway and epithelialmesenchymal transition. Hepatology 2020a;71:1262–1278.

[172] Liu W, Yin Y, Wang M et al. Disrupting phosphatase SHP2 in macrophages protects mice from high-fat diet-induced hepatic steatosis and insulin resistance by elevating IL-18 levels. J Biol Chem 2020b;295:10842–10856.

[173] Liu B, Xiang L, Ji J et al. Sparcl1 promotes nonalcoholic steatohepatitis progression in mice through upregulation of CCL2. J Clin Invest 2021;131:e144801.

[174] Liu CH, Zheng S, Wang S et al. Urine proteome in distinguishing hepatic steatosis in patients with metabolic-associated fatty liver disease. Diagnostics 2022;12:1412.

[175] Liu C, Schönke M, Spoorenberg B et al. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis. Elife 2023a;12:e83075.

[176] Liu J, Hu S, Chen L et al. Profiling the genome and proteome of metabolic dysfunction-associated steatotic liver disease identifies potential therapeutic targets. medRxiv 2023b;2023.11.30.23299247.

[177] Liu J, Jiang J, Li Y et al. Effects of FGF21 overexpression in osteoporosis and bone mineral density: a two-sample, mediating Mendelian analysis. Front Endocrinol 2024;15:1439255.

[178] Liu Z, Wei S, Jiang Y et al. Protein phosphatase 6 regulates metabolic dysfunction-associated steatohepatitis via the mTORC1 pathway. J Hepatol 2025;S0168-8278(25)00079-0.

[179] Locke AE, Kahali B, Berndt SI et al; LifeLines Cohort Study. Genetic studies of body mass index yield new insights for obesity biology. Nature 2015;518:197–206.

[180] Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 2021;184:2537–2564.

[181] Loomba R, Lawitz EJ, Frias JP et al. Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multipleascending-dose study. Lancet Gastroenterol Hepatol 2023a;8:120–132.

[182] Loomba R, Sanyal AJ, Kowdley KV et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. N Engl J Med 2023b;389:998–1008.

[183] Loomba R, Sanyal AJ, Nakajima A et al. Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): a randomized phase 2b study. Clin Gastroenterol Hepatol 2024;22:102–112.e9.

[184] Lopez-Bermejo A, Bosch M, Recasens M et al. Potential role of interleukin-18 in liver disease associated with insulin resistance. Obes Res 2005;13:1925–1931.

[185] Lou G, Zhang Q, Xiao F et al. Intranasal administration of TAT-haFGF_14–154 attenuates disease progression in a mouse model of Alzheimer’s disease. Neuroscience 2012;223:225–237.

[186] Lu JF, Zhu MQ, Xia B et al. GDF15 is a major determinant of ketogenic diet-induced weight loss. Cell Metab 2023;35:2165–2182.e7.

[187] Ludwiczek O, Kaser A, Novick D et al. Plasma levels of interleukin-18 and interleukin-18 binding protein are elevated in patients with chronic liver disease. J Clin Immunol 2002;22:331–337.

[188] Lundasen T, Galman C, Angelin B et al. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006;260:530–536.

[189] Luo Z, Lei H, Sun Y et al. Orosomucoid, an acute response protein with multiple modulating activities. J Physiol Biochem 2015;71:329–340.

[190] Macia L, Tsai VW, Nguyen AD et al. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) decreases food intake, body weight and improves glucose tolerance in mice on normal & obesogenic diets. PLoS One 2012;7:e34868.

[191] Maeda S, Imamura M, Kurashige M et al. Replication study for the association of 3 SNP loci identified in a genomewide association study for diabetic nephropathy in European type 1 diabetes with diabetic nephropathy in Japanese patients with type 2 diabetes. Clin Exp Nephrol 2013;17:866–871.

[192] Mahli A, Seitz T, Beckroge T et al. Bone morphogenetic protein-8B expression is induced in steatotic hepatocytes and promotes hepatic steatosis and inflammation in vitro. Cells 2019;8:457.

[193] Maltez VI, Tubbs AL, Cook KD et al. Inflammasomes coordinate pyroptosis and natural killer cell cytotoxicity to clear infection by a ubiquitous environmental bacterium. Immunity 2015;43:987–997.

[194] Maranon P, Fernandez-Garcia CE, Isaza SC et al. Bone morphogenetic protein 2 is a new molecular target linked to non-alcoholic fatty liver disease with potential value as non-invasive screening tool. Biomark Res 2022;10:35.

[195] Markan KR, Naber MC, Ameka MK et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes 2014;63:4057–4063.

[196] Markan KR, Potthoff MJ. Metabolic fibroblast growth factors (FGFs): mediators of energy homeostasis. Semin Cell Dev Biol 2016;53:85–93.

[197] Martinez C, Latorre J, Ortega F et al. Serum neuregulin 4 is negatively correlated with insulin sensitivity in humans and impairs mitochondrial respiration in HepG2 cells. Front Physiol 2022;13:950791.

[198] Marti-Pamies I, Thoonen R, Seale P et al. Deficiency of bone morphogenetic protein-3b induces metabolic syndrome and increases adipogenesis. Am J Physiol Endocrinol Metab 2020;319:E363–E375.

[199] Matsumoto Y, Otsuka F, Hino J et al. Bone morphogenetic protein-3b (BMP-3b) inhibits osteoblast differentiation via Smad2/3 pathway by counteracting Smad1/5/8 signaling. Mol Cell Endocrinol 2012;350:78–86.

[200] Mazzolini G, Atorrasagasti C, Onorato A et al. SPARC expression is associated with hepatic injury in rodents and humans with non-alcoholic fatty liver disease. Sci Rep 2018;8:725.

[201] Mehta R, Neupane A, Wang L et al. Expression of NALPs in adipose and the fibrotic progression of non-alcoholic fatty liver disease in obese subjects. BMC Gastroenterol 2014;14:208.

[202] Meissburger B, Perdikari A, Moest H et al. Regulation of adipogenesis by paracrine factors from adipose stromalvascular fraction -a link to fat depot-specific differences. Biochim Biophys Acta 2016;1861:1121–1131.

[203] Meng D, Pan H, Chen Y et al. Roles and mechanisms of NRG1 in modulating the pathogenesis of NAFLD through ErbB3 signaling in hepatocytes (NRG1 modulates NAFLD through ErbB3 signaling). Obes Res Clin Pract 2021;15:145–151.

[204] Meyer D, Yamaai T, Garratt A et al. Isoform-specific expression and function of neuregulin. Development 1997;124:3575–3586.

[205] Miao L, Targher G, Byrne CD et al. Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab 2024;35:697–707.

[206] Miller DL, Ortega S, Bashayan O et al. Compensation by fibroblast growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 null mice. Mol Cell Biol 2000;20:2260–2268.

[207] Moeckli B, Pham TV, Slits F et al. FGF21 negatively affects long-term female fertility in mice. Heliyon 2022;8:e11490.

[208] Moniruzzaman M, Wang R, Jeet V et al. Interleukin (IL)-22 from IL-20 subfamily of cytokines induces colonic epithelial cell proliferation predominantly through ERK1/2 pathway. Int J Mol Sci 2019;20:3468.

[209] Moriwaki Y, Yamamoto T, Shibutani Y et al. Elevated levels of interleukin-18 and tumor necrosis factor-α in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 2003;52:605–608.

[210] Mounika N, Yadav A, Kamboj P et al. Circulatory bone morphogenetic protein (BMP) 8B is a non-invasive predictive biomarker for the diagnosis of non-alcoholic steatohepatitis (NASH). PLoS One 2023;18:e0295839.

[211] Mraz M, Lacinova Z, Kavalkova P et al. Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-alpha agonist treatment. Physiol Res 2011;60:627–636.

[212] Mullican SE, Lin-Schmidt X, Chin CN et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat Med 2017;23:1150–1157.

[213] Murphy AJ, Kraakman MJ, Kammoun HL et al. IL-18 production from the NLRP1 inflammasome prevents obesity and metabolic syndrome. Cell Metab 2016;23:155–164.

[214] Musale V, Wasserman DH, Kang L. Extracellular matrix remodelling in obesity and metabolic disorders. Life Metab. 2023;2:load021.

[215] Muskiet MHA, Tonneijck L, Smits MM et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol 2017;13:605–628.

[216] Nakayasu ES, Syed F, Tersey SA et al. Comprehensive proteomics analysis of stressed human islets identifies GDF15 as a target for type 1 diabetes intervention. Cell Metab 2020;31:363–374.e6.

[217] Netea MG, Joosten LA. The NLRP1-IL18 connection: a stab in the back of obesity-induced inflammation. Cell Metab 2016;23:6–7.

[218] Netea MG, Joosten LA, Lewis E et al. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med 2006;12:650–656.

[219] Ouyang W, O’Garra A. IL-10 family cytokines IL-10 and IL-22: from basic science to clinical translation. Immunity 2019;50:871–891.

[220] Ouyang W, Rutz S, Crellin NK et al. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 2011;29:71–109.

[221] Owen BM, Ding X, Morgan DA et al. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab 2014;20:670–677.

[222] Park O, Wang H, Weng H et al. In vivo consequences of liverspecific interleukin-22 expression in mice: implications for human liver disease progression. Hepatology 2011;54:252–261.

[223] Peng Q, Chen B, Wang H et al. Bone morphogenetic protein 4 (BMP4) alleviates hepatic steatosis by increasing hepatic lipid turnover and inhibiting the mTORC1 signaling axis in hepatocytes. Aging 2019;11:11520–11540.

[224] Pera EM, Kim JI, Martinez SL et al. Isthmin is a novel secreted protein expressed as part of the Fgf-8 synexpression group in the Xenopus midbrain-hindbrain organizer. Mech Dev 2002;116:169–172.

[225] Petrova P, Raibekas A, Pevsner J et al. MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J Mol Neurosci 2003;20:173–188.

[226] Platko K, Lebeau PF, Byun JH et al. GDF10 blocks hepatic PPARgamma activation to protect against diet-induced liver injury. Mol Metab 2019;27:62–74.

[227] Potthoff MJ. FGF21 and metabolic disease in 2016: a new frontier in FGF21 biology. Nat Rev Endocrinol 2017;13:74–76.

[228] Potthoff MJ, Boney-Montoya J, Choi M et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway. Cell Metab 2011;13:729–738.

[229] Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev 2012;26:312–324.

[230] Presta I, Andreozzi F, Succurro E et al. IL-18 gene polymorphism and metabolic syndrome. Nutr Metab Cardiovasc Dis 2009;19:e5–e6.

[231] Qin Z, Wan JJ, Sun Y et al. ORM promotes skeletal muscle glycogen accumulation via CCR5-activated AMPK pathway in mice. Front Pharmacol 2016;7:302.

[232] Rader DJ, Maratos-Flier E, Nguyen A et al; CLLF580X2102 Study Team. LLF580, an FGF21 analog, reduces triglycerides and hepatic fat in obese adults with modest hypertriglyceridemia. J Clin Endocrinol Metab 2022;107:e57–e70.

[233] Rinella ME, Lieu HD, Kowdley KV et al. A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. Hepatology 2024;79:674–689.

[234] Robinson D, Shibuya K, Mui A et al. IGIF does not drive Th1 development but synergizes with IL-12 for interferongamma production and activates IRAK and NFkappaB. Immunity 1997;7:571–581.

[235] Rochette L, Zeller M, Cottin Y et al. Insights into mechanisms of GDF15 and receptor GFRAL: therapeutic targets. Trends Endocrinol Metab 2020;31:939–951.

[236] Rosset EM, Bradshaw AD. SPARC/osteonectin in mineralized tissue. Matrix Biol 2016;52–54:78–87.

[237] Ryu S, Sidorov S, Ravussin E et al. The matricellular protein SPARC induces inflammatory interferon-response in macrophages during aging. Immunity 2022;55:1609–1626.e7.

[238] Ryu S, Spadaro O, Sidorov S et al. Reduction of SPARC protects mice against NLRP3 inflammasome activation and obesity. J Clin Invest 2023;133:e169173.

[239] Sajiir H, Keshvari S, Wong KY et al. Liver and pancreatictargeted interleukin-22 as a therapeutic for metabolic dysfunction-associated steatohepatitis. Nat Commun 2024a;15:4528.

[240] Sajiir H, Wong KY, Muller A et al. Pancreatic beta-cell IL-22 receptor deficiency induces age-dependent dysregulation of insulin biosynthesis and systemic glucose homeostasis. Nat Commun 2024b;15:4527.

[241] Sakai H, Suzuki Y, Miyauchi Y et al. Downregulation of Sparclike protein 1 during cisplatin-induced inhibition of myogenic differentiation of C2C12 myoblasts. Biochem Pharmacol 2022;204:115234.

[242] Salazar-Leon J, Valdez-Hernandez AL, Garcia-Jimenez S et al. Nlrp1b1 negatively modulates obesity-induced inflammation by promoting IL-18 production. Sci Rep 2019;9:13815.

[243] Sancar G, Liu S, Gasser E et al. FGF1 and insulin control lipolysis by convergent pathways. Cell Metab 2022;34:171–183.e6.

[244] Sandholm N, Salem RM, McKnight AJ et al; DCCT/EDIC Research Group. New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet 2012;8:e1002921.

[245] Sanyal A, Charles ED, Neuschwander-Tetri BA et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebocontrolled, phase 2a trial. Lancet 2019;392:2705–2717.

[246] Scarlett JM, Muta K, Brown JM et al. Peripheral mechanisms mediating the sustained antidiabetic action of FGF1 in the brain. Diabetes 2019;68:654–664.

[247] Scarlett JM, Rojas JM, Matsen ME et al. Central injection of fibroblast growth factor 1 induces sustained remission of diabetic hyperglycemia in rodents. Nat Med 2016;22:800–806.

[248] Schlein C, Talukdar S, Heine M et al. FGF21 lowers plasma triglycerides by accelerating lipoprotein catabolism in white and brown adipose tissues. Cell Metab 2016;23:441–453.

[249] Sciarrillo CM, Keirns BH, Koemel NA et al. Fibroblast Growth Factor 19: potential modulation of hepatic metabolism for the treatment of non-alcoholic fatty liver disease. Liver Int 2021;41:894–904.

[250] Serti E, Werner JM, Chattergoon M et al. Monocytes activate natural killer cells via inflammasome-induced interleukin 18 in response to hepatitis C virus replication. Gastroenterology 2014;147:209–220.e3.

[251] Sigvardsen CM, Richter MM, Engelbeen S et al. GDF15 is still a mystery hormone. Trends Endocrinol Metab 2024:S1043-2760(24)00254-6.

[252] Sjoberg KA, Sigvardsen CM, Alvarado-Diaz A et al. GDF15 increases insulin action in the liver and adipose tissue via a beta-adrenergic receptor-mediated mechanism. Cell Metab 2023;35:1327–1340.e5.

[253] Smith WB, Nguyen D, Clough T et al. A growth-differentiation factor 15 receptor agonist in randomized placebocontrolled trials in healthy or obese persons. J Clin Endocrinol Metab 2024;110:771–786.

[254] Soberg S, Andersen ES, Dalsgaard NB et al. FGF21, a liver hormone that inhibits alcohol intake in mice, increases in human circulation after acute alcohol ingestion and sustained binge drinking at Oktoberfest. Mol Metab 2018;11:96–103.

[255] Somm E, Jornayvaz FR. Fibroblast Growth Factor 15/19: from basic functions to therapeutic perspectives. Endocr Rev 2018;39:960–989.

[256] Sousa-Victor P, Neves J, Cedron-Craft W et al. MANF regulates metabolic and immune homeostasis in ageing and protects against liver damage. Nat Metab 2019;1:276–290.

[257] South JC, Blackburn E, Brown IR et al. The neuregulin system of ligands and their receptors in rat islets of langerhans. Endocrinology 2013;154:2385–2392.

[258] Stanislaus S, Hecht R, Yie J et al. A novel Fc-FGF21 with improved resistance to proteolysis, increased affinity toward beta-Klotho, and enhanced efficacy in mice and cynomolgus monkeys. Endocrinology 2017;158:1314–1327.

[259] Suh JM, Jonker JW, Ahmadian M et al. Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. Nature 2014;513:436–439.

[260] Sullivan MM, Sage EH. Hevin/SC1, a matricellular glycoprotein and potential tumor-suppressor of the SPARC/BM-40/Osteonectin family. Int J Biochem Cell Biol 2004;36:991–996.

[261] Sun QJ, Cai LY, Jian J et al. The role of bone morphogenetic protein 9 in nonalcoholic fatty liver disease in mice. Front Pharmacol 2020;11:605967.

[262] Sun Y, Dai X, Yang J et al. Deficiency of hepatokine orosomucoid1 aggravates NAFLD progression in mice. Biochim Biophys Acta Mol Basis Dis 2025;1871:167654.

[263] Sun Y, Yang Y, Qin Z et al. The acute-phase protein orosomucoid regulates food intake and energy homeostasis via leptin receptor signaling pathway. Diabetes 2016;65:1630–1641.

[264] Suzuki S, Li AJ, Ishisaki A et al. Feeding suppression by fibroblast growth factor-1 is accompanied by selective induction of heat shock protein 27 in hypothalamic astrocytes. Eur J Neurosci 2001;13:2299–2308.

[265] Suzuki M, Uehara Y, Motomura-Matsuzaka K et al. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol 2008;22:1006–1014.

[266] Talukdar S, Zhou Y, Li D et al. A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab 2016;23:427–440.

[267] Tang KY, Lickliter J, Huang ZH et al. Safety, pharmacokinetics, and biomarkers of F-652, a recombinant human interleukin-22 dimer, in healthy subjects. Cell Mol Immunol 2019;16:473–482.

[268] Thayer TE, Lino Cardenas CL, Martyn T et al. The role of bone morphogenetic protein signaling in non-alcoholic fatty liver disease. Sci Rep 2020;10:9831.

[269] Tilg H, Byrne CD, Targher G. NASH drug treatment development: challenges and lessons. Lancet Gastroenterol Hepatol 2023;8:943–954.

[270] Tomlinson E, Fu L, John L et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002;143:1741–1747.

[271] Tran T, Yang J, Gardner J et al. GDF15 deficiency promotes high fat diet-induced obesity in mice. PLoS One 2018;13:e0201584.

[272] Tsai VW, Manandhar R, Jorgensen SB et al. The anorectic actions of the TGFbeta cytokine MIC-1/GDF15 require an intact brainstem area postrema and nucleus of the solitary tract. PLoS One 2014;9:e100370.

[273] Tutunchi H, Mobasseri M, Aghamohammadzadeh N et al. Serum neuregulin 4 (NRG-4) level and non-alcoholic fatty liver disease (NAFLD): a case-control study. Int J Clin Pract 2021;75:e14555.

[274] Vacca M, Leslie J, Virtue S et al. Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis. Nat Metab 2020;2:514–531.

[275] Villarroya F, Cereijo R, Villarroya J et al. Brown adipose tissue as a secretory organ. Nat Rev Endocrinol 2017;13:26–35.

[276] von Holstein-Rathlou S, BonDurant LD, Peltekian L et al. FGF21 mediates endocrine control of simple sugar intake and sweet taste preference by the liver. Cell Metab 2016;23:335–343.

[277] Walters JR. Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol 2014;11:426–434.

[278] Wan JJ, Wang PY, Zhang Y et al. Role of acute-phase protein ORM in a mice model of ischemic stroke. J Cell Physiol 2019;234:20533–20545.

[279] Wang GX, Zhao XY, Meng ZX et al. The brown fat-enriched secreted factor Nrg4 preserves metabolic homeostasis through attenuation of hepatic lipogenesis. Nat Med 2014a;20:1436–1443.

[280] Wang X, Chrysovergis K, Kosak J et al. Lower NLRP3 inflammasome activity in NAG-1 transgenic mice is linked to a resistance to obesity and increased insulin sensitivity. Obesity 2014b;22:1256–1263.

[281] Wang X, Chrysovergis K, Kosak J et al. hNAG-1 increases lifespan by regulating energy metabolism and insulin/IGF-1/mTOR signaling. Aging 2014c;6:690–704.

[282] Wang X, Ota N, Manzanillo P et al. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature 2014d;514:237–241.

[283] Wang R, Yang F, Qing L et al. Decreased serum neuregulin 4 levels associated with non-alcoholic fatty liver disease in children with obesity. Clin Obes 2019a;9:e12289.

[284] Wang Y, Huang S, Yu P. Association between circulating neuregulin4 levels and diabetes mellitus: a meta-analysis of observational studies. PLoS One 2019b;14:e0225705.

[285] Wang Y, Liu S, Yan Y et al. SPARCL1 promotes C2C12 cell differentiation via BMP7-mediated BMP/TGF-beta cell signaling pathway. Cell Death Dis 2019c;10:852.

[286] Wang X, Ma B, Wen X et al. Bone morphogenetic protein 4 alleviates nonalcoholic steatohepatitis by inhibiting hepatic ferroptosis. Cell Death Discov 2022a;8:234.

[287] Wang Y, Chen C, Chen J et al. Overexpression of NAG-1/GDF15 prevents hepatic steatosis through inhibiting oxidative stress-mediated dsDNA release and AIM2 inflammasome activation. Redox Biol 2022b;52:102322.

[288] Wei W, Dutchak PA, Wang X et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma. Proc Natl Acad Sci U S A 2012;109:3143–3148.

[289] Wu AL, Kolumam G, Stawicki S et al. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci Transl Med 2011;3:113ra126.

[290] Wu T, Liu Q, Li Y et al. Feeding-induced hepatokine, Manf, ameliorates diet-induced obesity by promoting adipose browning via p38 MAPK pathway. J Exp Med 2021;218:e20201203.

[291] Wu LF, Zhou ZJ, Zeng YH et al. Circular RNA RRM2 alleviates metabolic dysfunction-associated steatotic liver disease by targeting miR-142-5p to increase NRG1 expression. Am J Physiol Gastrointest Liver Physiol 2024;327:G485–G498.

[292] Xiang L, Li X, Luo Y et al. A multi-omic landscape of steatosisto-NASH progression. Life Metab. 2022;1:242–257.

[293] Xiao C, Jin HG, Zhang LC et al. Effects of SPARCL1 on the proliferation and differentiation of sheep preadipocytes. Adipocyte 2021;10:658–669.

[294] Xiao YT, Xiang LX, Shao JZ. Bone morphogenetic protein. Biochem Biophys Res Commun 2007;362:550–553.

[295] Xie Z, Li Y, Cheng L et al. Potential therapeutic strategies for MASH: from preclinical to clinical development. Life Metab 2024;3:loae029.

[296] Xu J, Lloyd DJ, Hale C et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009a;58:250–259.

[297] Xu J, Stanislaus S, Chinookoswong N et al. Acute glucoselowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models—association with liver and adipose tissue effects. Am J Physiol Endocrinol Metab 2009b;297:E1105–E1114.

[298] Xu Z, Wu Y, Wang F et al. Fibroblast growth factor 1 ameliorates diabetes-induced liver injury by reducing cellular stress and restoring autophagy. Front Pharmacol 2020;11:52.

[299] Yamanishi K, Maeda S, Kuwahara-Otani S et al. Interleukin-18-deficient mice develop dyslipidemia resulting in nonalcoholic fatty liver disease and steatohepatitis. Transl Res 2016;173:101–114.e7.

[300] Yan J, Liu Q, Tang Q et al. Mesencephalic astrocytederived neurotrophic factor alleviates non-alcoholic steatohepatitis induced by Western diet in mice. FASEB J 2022;36:e22349.

[301] Yang L, Chang CC, Sun Z et al. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nat Med 2017;23:1158–1166.

[302] Yang L, Zhang Y, Wang L et al. Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22. J Hepatol 2010;53:339–347.

[303] Yang Y, Gu M, Wang W et al. Circulating Bone morphogenetic protein 9 (BMP9) as a new biomarker for noninvasive stratification of nonalcoholic fatty liver disease and metabolic syndrome. Clin Exp Med 2024;24:55.

[304] Yang Z, Li P, Shang Q et al. CRISPR-mediated BMP9 ablation promotes liver steatosis via the down-regulation of PPARα expression. Sci Adv 2020;6:eabc5022.

[305] Ye D, Wang Y, Li H et al. Fibroblast growth factor 21 protects against acetaminophen-induced hepatotoxicity by potentiating peroxisome proliferator-activated receptor coactivator protein-1α-mediated antioxidant capacity in mice. Hepatology 2014;60:977–989.

[306] Younossi ZM, Stepanova M, Racila A et al. Health-related quality of life (HRQL) assessments in a 52-week, doubleblind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. Hepatology 2025;81:1318–1327.

[307] Yu F, Xie S, Wang T et al. Pancreatic β cell interleukin-22 receptor subunit alpha 1 deficiency impairs β cell function in type 2 diabetes via cytochrome b5 reductase 3. Cell Rep 2024;43:115057.

[308] Zaharieva E, Kamenov Z, Velikova T et al. Interleukin-18 serum level is elevated in type 2 diabetes and latent autoimmune diabetes. Endocr Connect 2018;7:179–185.

[309] Zai W, Chen W, Wu Z et al. Targeted interleukin-22 gene delivery in the liver by polymetformin and penetratin-based hybrid nanoparticles to treat nonalcoholic fatty liver disease. ACS Appl Mater Interfaces 2019;11:4842–4857.

[310] Zarei M, Barroso E, Palomer X et al. Hepatic regulation of VLDL receptor by PPARbeta/delta and FGF21 modulates non-alcoholic fatty liver disease. Mol Metab 2018;8:117–131.

[311] Zeng F, Wang Y, Kloepfer LA et al. ErbB4 deletion predisposes to development of metabolic syndrome in mice. Am J Physiol Endocrinol Metab 2018;315:E583–E593.

[312] Zhang L, Bai M, Tang H et al. Role of hepatic neuregulin 4 in the regulation of gluconeogenesis in mice. Life Sci 2019;217:185–192.

[313] Zhang P, Chen Z, Kuang H et al. Neuregulin 4 suppresses NASH-HCC development by restraining tumor-prone liver microenvironment. Cell Metab 2022;34:1359–1376.e7.

[314] Zhang L, Fu Y, Zhou N et al. Circulating neuregulin 4 concentrations in patients with newly diagnosed type 2 diabetes: a cross-sectional study. Endocrine 2017;57:535–538.

[315] Zhang P, Kuang H, He Y et al. NRG1-Fc improves metabolic health via dual hepatic and central action. JCI Insight 2018;3:e98522.

[316] Zhang H, Lei S, Zhuo H et al. TRIM24 up-regulates ORM2 to alleviate abnormal lipid metabolism, inflammation, and oxidative stress in mice with obstructive sleep apnea syndrome and metabolic dysfunction-associated steatotic liver disease. Am J Pathol 2024a;194:2091–2105.

[317] Zhang P, Liu J, Lee A et al. IL-22 resolves MASLD via enterocyte STAT3 restoration of diet-perturbed intestinal homeostasis. Cell Metab 2024b;36:2341–2354.e6.

[318] Zhang S, Yang X, Wang W. Associations of genetic polymorphisms in CTLA-4 and IL-18 with chronic liver diseases: evidence from a meta-analysis. Genomics 2020;112:1889–1896.

[319] Zhang Y, Zhao X, Dong X et al. Activity-balanced GLP-1/GDF15 dual agonist reduces body weight and metabolic disorder in mice and non-human primates. Cell Metab 2023a;35:287–298.e4.

[320] Zhang Y, Zhu Y, Wang J et al. Neuregulin4 acts on hypothalamic ErBb4 to excite oxytocin neurons and preserve metabolic homeostasis. Adv Sci 2023b;10:e2204824.

[321] Zhao Q, Wu J, Ding Y et al. Gut microbiota, immunity, and bile acid metabolism: decoding metabolic disease interactions. Life Metab. 2023;2:load032.

[322] Zhou M, Learned RM, Rossi SJ et al. Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice. Hepatol Commun 2017;1:1024–1042.

[323] Zhou B, Luo Y, Ji N et al. Orosomucoid 2 maintains hepatic lipid homeostasis through suppression of de novo lipogenesis. Nat Metab 2022;4:1185–1201.

[324] Zhou M, Wang X, Phung V et al. Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19. Cancer Res 2014;74:3306–3316.

[325] Zhu X, Wang X, Wang J et al. Intermittent fasting-induced Orm2 promotes adipose browning via the GP130/IL23R-p38 cascade. Adv Sci 2024;11:e2407789.

[326] Zhuang H, Han J, Cheng L et al. A positive causal influence of IL-18 levels on the risk of T2DM: a Mendelian randomization study. Front Genet 2019;10:295.

[327] Ziqubu K, Dludla PV, Mthembu SXH et al. Low circulating levels of neuregulin 4 as a potential biomarker associated with the severity and prognosis of obesity-related metabolic diseases: a systematic review. Adipocyte 2024;13:2390833.

RIGHTS & PERMISSIONS

The Author(s) 2025. Published by Oxford University Press on behalf of Higher Education Press.